Lakefront Biotherapeutics (GXEA) Stock Statistics & Valuation Metrics
Total Valuation
Lakefront Biotherapeutics has a market cap or net worth of EUR 1.91B. The enterprise value is -EUR 451.30M.
- Market Cap
- EUR 1.91B
- Enterprise Value
- -EUR 451.30M
Share Statistics
Lakefront Biotherapeutics has 65,897,070 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 65,897,070
- Owned by Insiders
- ―
- Owned by Institutions
- 2.03%
Financial Efficiency
Lakefront Biotherapeutics’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 15.40%.
- Return on Equity (ROE)
- 0.10
- Return on Assets (ROA)
- 0.09
- Return on Invested Capital (ROIC)
- 15.40%
- Return on Capital Employed (ROCE)
- 0.15
- Revenue Per Employee
- 2.46M
- Profits Per Employee
- 709.92K
- Employee Count
- 452
- Asset Turnover
- 0.33
- Inventory Turnover
- 1.32
Valuation Ratios
The current PE Ratio of Lakefront Biotherapeutics is 3.91. Lakefront Biotherapeutics’s PEG ratio is -0.10.
- PE Ratio
- 3.91
- PS Ratio
- 1.82
- PB Ratio
- 0.59
- Price to FCF
- -6.31
- Price to Operating Cash Flow
- -6.52
- PEG Ratio
- -0.10
Income Statement
In the last 12 months, Lakefront Biotherapeutics had revenue of 1.11B and earned 320.88M in profits. Earnings per share was 4.87.
- Revenue
- 1.11B
- Gross Profit
- 1.08B
- Operating Income
- 501.39M
- Pretax Income
- 300.87M
- Net Income
- 320.88M
- EBITDA
- 358.96M
- Earnings Per Share (EPS)
- 4.87
Cash Flow
In the last 12 months, operating cash flow was -192.82M and capital expenditures -4.58M, giving a free cash flow of -197.40M billion.
- Operating Cash Flow
- -192.82M
- Free Cash Flow
- -197.40M
- Free Cash Flow per Share
- -4.57
Dividends & Yields
Lakefront Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -15.86%
- Earnings Yield
- 25.65%
Stock Price Statistics
- Beta
- 0.19
- 52-Week Price Change
- 8.27%
- 50-Day Moving Average
- 25.64
- 200-Day Moving Average
- 25.67
- Relative Strength Index (RSI)
- 71.78
- Average Volume (3m)
- 500
Important Dates
Lakefront Biotherapeutics upcoming earnings date is Nov 12, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 10, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
Lakefront Biotherapeutics as a current ratio of 20.15, with Debt / Equity ratio of 0.21%
- Current Ratio
- 20.15
- Quick Ratio
- 20.00
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.23
- Interest Coverage Ratio
- 226.16
Taxes
In the past 12 months, Lakefront Biotherapeutics has paid -18.62M in taxes.
- Income Tax
- -18.62M
- Effective Tax Rate
- -0.06
Enterprise Valuation
Lakefront Biotherapeutics EV to EBITDA ratio is 5.30, with an EV/FCF ratio of -6.11.
- EV to Sales
- 1.76
- EV to EBITDA
- 5.30
- EV to Free Cash Flow
- -6.11
- EV to Operating Cash Flow
- -6.29
Balance Sheet
Lakefront Biotherapeutics has EUR 2.24B in cash and marketable securities with EUR 6.36M in debt, giving a net cash position of EUR 2.23B billion.
- Cash & Marketable Securities
- EUR 2.24B
- Total Debt
- EUR 6.36M
- Net Cash
- EUR 2.23B
- Net Cash Per Share
- EUR 33.88
- Tangible Book Value Per Share
- EUR 38.26
Margins
Gross margin is 98.01%, with operating margin of 36.43%, and net profit margin of 46.83%.
- Gross Margin
- 98.01%
- Operating Margin
- 36.43%
- Pretax Margin
- 45.14%
- Net Profit Margin
- 46.83%
- EBITDA Margin
- 33.26%
- EBIT Margin
- 30.70%
Analyst Forecast
The average price target for Lakefront Biotherapeutics is EUR 31.68, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 31.68
- Price Target Upside
- 10.00% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- 259.41%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 6
- AI Score
- ―
